Acute Interleukin-6 Administration Impairs Athletic Performance in Healthy, Trained Male Runners

Fatigue is an inevitable consequence of physical activity; yet its biological cause remains uncertain. During exercise, a polypeptide messenger molecule interleukin-6 (IL-6) is actively produced. Previously, the administration of recombinant IL-6 (rhIL-6) induced a heightened sensation of fatigue in...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of applied physiology 2004-08, Vol.29 (4), p.411-418
Main Authors: Robson-Ansley, Paula J, Milander, Liesl de, Collins, Malcolm, Noakes, Timothy D
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Drug therapy
Exercise
Exercise Test - drug effects
Fatigue
Fundamental and applied biological sciences. Psychology
Health aspects
Humans
Interleukin-6
Interleukin-6 - administration & dosage
Interleukin-6 - blood
Interleukin-6 - pharmacology
Male
Muscle Fatigue - drug effects
Recombinant Proteins - administration & dosage
Recombinant Proteins - adverse effects
Running
Vertebrates: body movement. Posture. Locomotion. Flight. Swimming. Physical exercise. Rest. Sports
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fatigue is an inevitable consequence of physical activity; yet its biological cause remains uncertain. During exercise, a polypeptide messenger molecule interleukin-6 (IL-6) is actively produced. Previously, the administration of recombinant IL-6 (rhIL-6) induced a heightened sensation of fatigue in healthy humans at rest. In contrast, anti-IL-6 receptor antibodies reduced the symptoms of chronic fatigue. In the present study, athletic performance during an exercise challenge consisting of a 10-km running time trial was significantly impaired in trained male runners following the administration of a low dose of rhIL-6 compared to the placebo trial. Key words: prolonged exercise, fatigue, exercise challenge
ISSN:1066-7814
1543-2718
DOI:10.1139/h04-026